CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Exercise or conversion COO and Secretary acquired 7,043 shares (option exercise)
- 4 Open-market sale Chief Medical Officer sold 17,500 shares at $19.05 ($333,375)
- 4 Open-market sale President and CEO sold 18,333 shares at $19.06 ($349,427)
- 4 Open-market sale Chief Medical Officer sold 17,500 shares at $18.04 ($315,700)
- 4 Open-market sale President and CEO sold 18,334 shares at $18.05 ($330,929)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion COO and Secretary acquired 5,918 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Insider Changes in Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 20 of 22 · 436 filings